心脏生物标志物的性别特异性阈值——我们需要向前迈进。
Sex-Specific Thresholds for Cardiac Biomarkers-We Need to Move Forward.
作者信息
Lobo Ronstan, Jaffe Allan S
机构信息
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
出版信息
Rev Cardiovasc Med. 2023 Mar 8;24(3):86. doi: 10.31083/j.rcm2403086. eCollection 2023 Mar.
Cardiovascular biomarkers play a major diagnostic role for cardiologists. Different biomarkers provide different insights into a variety of cardiovascular conditions and in doing so they improve diagnosis and management. Often, these biomarkers are deployed without carefully evaluating the use of sex-specific cut off values. It is now becoming apparent that the use of such cut off values can improve prognostication and discrimination in some clinical situations. This review paper will focus on the data indicating that there is benefit to the use of sex-specific thresholds. It should be clear that these thresholds will vary depending on the analyte being measured and the specific clinical indication for which the patients are being evaluated; and sex-specific cut off values may be important in some situations but not others. Nonetheless, it is now clear that when evaluating sex-specific cut off values, one often finds benefit. We will highlight these situations using specific cardiac biomarkers as examples.
心血管生物标志物对心脏病专家起着主要的诊断作用。不同的生物标志物能为各种心血管疾病提供不同的见解，从而改善诊断和治疗。通常，这些生物标志物在使用时并未仔细评估性别特异性临界值的应用。现在越来越明显的是，在某些临床情况下，使用此类临界值可以改善预后评估和鉴别诊断。这篇综述文章将聚焦于表明使用性别特异性阈值有益的数据。需要明确的是，这些阈值会因所测量的分析物以及评估患者的具体临床指征而异；性别特异性临界值在某些情况下可能很重要，但在其他情况下并非如此。尽管如此，现在很清楚的是，在评估性别特异性临界值时，往往会发现其益处。我们将以特定的心脏生物标志物为例突出这些情况。
Zotero 插件